First AD

Second AD

Cytoreductive Therapy in PV Treatment Paradigm 

Video content above is prompted by the following:

Where does cytoreductive therapy fall in your treatment paradigm for patients with PV?

Briefly comment on the original findings from the CYTO-PV study

Video Series

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

ASH 2024: Polycythemia Vera and Myelofibrosis: Current and Future Standards of Care  

Peer Exchange

Panelists discuss how cytoreductive therapy fits into the treatment paradigm for polycythemia vera (PV), highlighting key findings from the CYTO-PV study and its subanalysis, which inform their treatment decisions for patients with PV.